Back to Search Start Over

Flow cytometric immunophenotypic features of acute myeloid leukemia with mast cell differentiation.

Authors :
Xu J
Kim DH
Wang W
Li S
Lin P
Tang G
Konoplev S
Qiu L
Fang H
Garces S
Leventaki V
E S
Medeiros LJ
Wang SA
Source :
American journal of clinical pathology [Am J Clin Pathol] 2024 Sep 08. Date of Electronic Publication: 2024 Sep 08.
Publication Year :
2024
Publisher :
Ahead of Print

Abstract

Objectives: Acute myeloid leukemia (AML) with mast cell (MC) differentiation was recently described as an aggressive subgroup of AML cases. The objectives of this study were to assess the flow cytometric immunophenotypic features of AML-MC cases.<br />Methods: We characterized the immunophenotypic features of 21 AML-MC cases by flow cytometry and compared them to 20 reactive/regenerating bone marrow specimens.<br />Results: The number of MCs detected by flow cytometry in AML-MC cases ranged from 0.4% to 21.1%, with a median of 3.5%, significantly higher than that of normal/reactive bone marrow (BM) (median, 0.01%; range, 0.000%-0.396%; P < .0001). Immunophenotypically, MCs in AML-MC cases demonstrated immaturity, differing from MCs in normal/reactive BMs, including dimmer CD45 (100% vs 0%), lower side scatter (100% vs 0%), more frequent CD34 (81% vs 20%), and CD123 (100% vs 10%) positivity, and more frequent uniform/increased CD38 expression (95% vs 20%) (all P ≤ .0001). CD2 (0/5) and CD25 (2/6, 1 uniform and 1 partial) were assessed in a subset of cases. The myeloblasts in AML-MC were typically CD34+CD117+HLA-DR+ with unusually frequent expression of CD56 (57%, all partial) and CD25 (63%, mostly partial), increased CD117 (62%), and decreased CD38 (86%). The MC percentage determined by flow cytometry correlated well with MCs detected by tryptase immunohistochemistry (r = 0.76, P < .001).<br />Conclusions: The MCs in AML-MC cases are characterized by dim CD45, low side scatter, CD34 and CD123 positivity, and uniform and increased CD38 expression. Flow cytometry is an excellent tool for identifying AML-MC cases.<br /> (© The Author(s) 2024. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)

Details

Language :
English
ISSN :
1943-7722
Database :
MEDLINE
Journal :
American journal of clinical pathology
Publication Type :
Academic Journal
Accession number :
39244687
Full Text :
https://doi.org/10.1093/ajcp/aqae116